No evidence of a role for mutations or polymorphisms of the follicle- stimulating hormone receptor in ovarian granulosa cell tumors

Journal of Clinical Endocrinology and Metabolism

Volumn 83, Issue 1, 1998, Pages 274-279

  Fuller, Peter J ^a,b,c   Verity, Karen ^a   Shen, Yan ^a   Mamers, Pamela ^a   Jobling, Tom ^a   Burger, Henry G ^a  

^a MONASH UNIVERSITY   (Australia)

^b HUDSON INSTITUTE OF MEDICAL RESEARCH   (Australia)

^c Natl Hlth Med Res Cncl A   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

FOLLITROPIN; FOLLITROPIN RECEPTOR; INHIBIN;

ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; FEMALE; GENE MUTATION; GRANULOSA CELL TUMOR; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN POLYMORPHISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SINGLE STRAND CONFORMATION POLYMORPHISM;

ALLELES; AMINO ACID SEQUENCE; BASE SEQUENCE; CODON; DNA, NEOPLASM; EXONS; FEMALE; GRANULOSA CELL TUMOR; HUMANS; MODELS, MOLECULAR; MUTATION; OVARIAN NEOPLASMS; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PROTEIN CONFORMATION; RECEPTORS, FSH;

EID: 0031765697     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.83.1.274     Document Type: Article

References (37)

1. Russell P, Bannatyne P. 1989 Surgical pathology of the ovaries. Edinburgh: Churchill Livingstone.
2. Lappohn RE, Burger HG, Bouma J, Bangah M, Krams M, de Bruijn HW. 1989 Inhibin as a marker for granulosa cell tumours. N Engl J Med. 321:790-793.
3. Healy DL, Burger HG, Mamers P, et al. 1993 Inhibin: a serum marker for mucinous ovarian cancers. N Engl J Med. 329:1539-1542.
4. Jobling T, Mamers F, Healy DL, MacLachlan V, Burger HG, Day AJ. 1994 A prospective study of inhibin in granulosa cell tumors of the ovary. Gynecol Oncol. 55:285-289.
5. Gustafson ML, Lee MM, Scully RE, et al. 1992 Müllerian inhibiting substance as a marker for ovarian sex-cord tumor. N Engl J Med. 326:466-471.
6. Sicinski P, Donaher JL, Geng Y, et al. 1996 Cyclin D2 is an FSH-responsive gene involved in gonadal cell proliferation and oncogenesis. Nature. 384:470-474.
7. Dhanasekaran N, Heasley LE, Johnson GL. 1995 G protein-coupled receptor systems involved in cell growth and oncogenesis. Endocr Rev. 16:259-270.
8. Spiegel AM. 1996 Genetic basis of endocrine disease: mutations in G proteins and G protein-coupled receptors in endocrine disease. J Clin Endocrinol Metab. 81:2434-2442.
9. Landis CA, Masters SB, Spada A, Pace AM, Bourne HR, Vallar L. 1989 GTPase inhibiting mutations activate the α-chain of Gs and stimulate adenylyl cyclase in human pituitary tumours. Nature. 340:692-696.
10. Lyons J, Landis CA, Harsh G, et al. 1990 Two G protein oncogenes in human endocrine tumors. Science. 249:655-659.
11. Shen Y, Mamers P, Jobling T, Burger HG, Fuller PJ. 1996 Absence of the previously reported G-protein oncogene (gip2) in ovarian granulosa cell tumors. J Clin Endocrinol Metab. 81:4159-4161.
12. Reincke M, Karl M, Travis W, Chrousos GP. 1993 No evidence for oncogenic mutations in guanine nucleotide-binding proteins of human adrenocortical neoplasms. J Clin Endocrinol Metab.77:1419-1422.
13. Parma J, Duprez L, Van Sande J, et al. 1993 Somatic mutations in the thyrotropin receptor gene cause hyperfunctioning thyroid adenomas. Nature. 365:649-651.
14. Russo D, Arturi F, Wicker R, et al. 1995 Genetic alterations in thyroid hyperfunctioning adenomas. J Clin Endocrinol Metab. 80:1347-1351.
15. Russo D, Arturi F, Schlumberger M, et al. 1995 Activating mutations of the TSH receptor in differentiated thyroid carcinomas. Oncogene. 11:1907-1911.
16. Spambalg D, Sharifi N, Elisei R, Gross JL, Medeiros-Neto G, Fagin JA. 1996 Structural studies of the thyrotropin receptor and Gsα in human thyroid cancers: low prevalence of mutations predicts infrequent involvement in malignant transformation. J Clin Endocrinol Metab. 81:3898-3901.
17. Murphy PM. 1997 Pirated genes in Kaposi's sarcoma. Nature. 385:296-299.
18. Orita M, Suzuki Y, Sekiya T, Hayashi K. 1989 Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction. Genomics. 5:874-879.
19. Aittomäki K, Lucena JLD, Pakarinen P, et al. 1995 Mutation in the follicle-stimulating hormone receptor gene causes hereditary hypergonadotropic ovarian failure. Cell 82:959-968.
20. Gromoll J, Simoni M, Nieschlag E. 1996 An activating mutation of the follicle-stimulating hormone receptor autonomously sustains spermatogenesis in a hypophysectomized man. J Clin Endocrinol Metab. 81:1367-1370.
21. Kotlar TJ, Young RH, Albanese C, Crowley Jr WF, Scully RE, Jameson JL. 1997 A mutation in the follicle-stimulating hormone receptor occurs frequently in human ovarian sex cord tumors. J Clin Endocrinol Metab. 82:1020-1026.
22. Willemsen W, Kruitwagen R, Bastiaans B, Hanselaar T, Rolland R. 1993 Ovarian stimulation and granulosa-cell tumour. Lancet. 341:986-988.
23. Rossing MA, Daling JR, Weiss NS, Moore DE, Self SG. 1994 Ovarian tumors in a cohort of infertile women. N Engl J Med. 331:771-776.
24. Venn A, Watson L, Lumley J, Giles G, King C, Healy D. 1995 Breast and ovarian cancer incidence after infertility and in vitro fertilisation. Lancet. 346:995-1000.
25. Rossing MA. 1996 Ovarian cancer: a risk of infertility treatment? J Br Fertil Soc. 1:46-50.
26. Matsuk MM, Finegold MJ, Su J-GJ, Hsueh AEW, Bradley A. 1992 α-Inhibin is a tumour-suppressor gene with gonadal specificity in mice. Nature. 360:313-319.
27. Schipani E, Langman CB, Parfitt AM, et al. 1996 Constitutively activated receptors for parathyroid hormone and parathyroid hormone-related peptide in Jansen's metaphyseal chondrodysplasia. N Engl J Med. 335:708-714.
28. Tonacchera M, Van Sande J, Cetani F, et al. 1996 Functional characteristics of three new germline mutations of the thyrotropin receptor gene causing autosomal dominant toxic thyroid hyperplasia. J Clin Endocrinol Metab. 81:547-554.
29. Shenker A, Laue L, Kosugi S, Merendino Jr JJ, Minegishi T, Cutler Jr GB. 1993 A constitutively activating mutation of the luteinizing hormone receptor in familial male precocious puberty. Nature. 365:652-654.
30. Kremer H, Mariman E, Otten BJ, et al. 1993 Cosegregation of missense mutations of the luteinizing hormone receptor gene with familial male-limited precocious puberty. Hum Mol Genet. 2:1779-1783.
31. Richard F, Martinat N, Remy J-J, Salesse R, Combarnous Y. 1997 Cloning, sequencing and in vitro functional expression of recombinant donkey follicle-stimulating hormone receptor: a new insight into the binding specificity of gonadotrophin receptors. J Mol Endocrinol. 18:193-202.
32. Gromoll J, Simoni M, Nordhoff V, Behre HM, De Geyter C, Nieschlag E. 1996 Functional and clinical consequences of mutations in the FSH receptor. Mol Cell Endocrinol. 125:177-182.
33. Graves PE, Surwit EA, Davis JR, Stouffer RL. 1985 Adenylate cyclase in human ovarian cancers: sensitivity to gonadotropins and nonhormonal activators. Am J Obstet Gynecol. 153:877-882.
34. Stouffer RL, Grodin MS, Davis JR, Surwit EA. 1984 Investigation of binding sites for follicle-stimulating hormone and chorionic gonadotropin in human ovarian cancers. J Clin Endocrinol Metab. 59:441-446.
35. Ratronico AC, Reincke M, Mendonca BB, et al. 1995 No evidence for oncogenic mutations in the adrenocorticotropin receptor gene in human adrenocortical neoplasms. J Clin Endocrinol Metab. 80:875-877.
36. Minegish T, Nakamura K, Takakura Y, Ibuki Y, Igarashi M. 1991 Cloning and sequencing of human FSH receptor cDNA. Biochem Biophys Res Commun. 175:1125-1130.
37. Gromoll J, Ried T, Holtgreve-Grez H, Nieschlag E, Gudermann T. 1994 Localization of the human FSH receptor to chromosome 2 p21 using a genomic probe comprising exon 10. J Mol Endocrinol. 12:265-271.